KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $209,994 | -82.4% | 6,587 | -77.8% | 0.00% | – |
| Q2 2023 | $1,193,989 | -15.4% | 29,716 | -10.1% | 0.00% | -100.0% |
| Q1 2023 | $1,411,278 | -40.2% | 33,051 | -32.8% | 0.00% | 0.0% |
| Q4 2022 | $2,361,576 | -61.6% | 49,179 | -69.9% | 0.00% | -66.7% |
| Q3 2022 | $6,142,000 | +12.9% | 163,239 | -17.1% | 0.00% | +50.0% |
| Q2 2022 | $5,441,000 | -49.9% | 196,915 | -1.4% | 0.00% | -50.0% |
| Q1 2022 | $10,858,000 | +19.3% | 199,683 | +28.3% | 0.00% | +33.3% |
| Q4 2021 | $9,105,000 | +77.3% | 155,615 | +19.9% | 0.00% | +50.0% |
| Q3 2021 | $5,135,000 | +8458.3% | 129,782 | +9039.6% | 0.00% | – |
| Q2 2021 | $60,000 | -93.7% | 1,420 | -90.9% | 0.00% | – |
| Q1 2021 | $958,000 | +5222.2% | 15,567 | +6151.8% | 0.00% | – |
| Q4 2020 | $18,000 | -78.3% | 249 | -88.7% | 0.00% | – |
| Q2 2020 | $83,000 | – | 2,207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |